Introduction: Severe asthma (SA) affects 5-15% of asthmatic patients, carrying a high clinical and economic burden. Heterogeneity exists in its presentation and management, with limited information in Latin America. The ALAT's Latin American Severe Asthma Registry (REAL) was designed to characterize this population in the region. Primary objective: To describe the natural history and the clinical, functional, phenotypic, and therapeutic characteristics of patients with SA in Latin America. Methods: Observational, prospective, multicenter study in specialized centers across Latin America. Patients ≥ 18 years old diagnosed with SA according to ALAT/ERS/ATS criteria, providing informed consent, were included. Three visits (baseline, 6, and 12 months) recorded demographic, clinical (symptom control via ACT, exacerbations, systemic corticosteroids, hospitalizations), functional (spirometry), biomarker (eosinophils, IgE, prick test, FeNO if available), comorbidity, treatment (including biologics), and adherence (TAI) variables. Data will be managed using REDCap. Descriptive and comparative analyses will be performed; prognostic factors will be explored using regression models. Ethical Considerations: The protocol requires approval from each participating center's Ethics Committee. Written informed consent will be obtained. Data confidentiality will be ensured. Discussion/Expected Outcomes: The REAL Registry will generate specific information on SA in Latin America, allowing the identification of prevalent phenotypes and the evaluation of real-world treatment patterns (to assess the response in the subgroup of patients treated with biologics) and clinical outcomes. This will contribute to optimizing management, guiding public health strategies and fostering research adapted to the region.